Skip to main content

Response to “Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis”

To the Editor,

We read with great interest the recent paper by Verroken et al. who describe the use of rapid molecular testing in critically ill COVID-19 patients to analyse the respiratory co-infection rate [1]. We agree that rapid detection and optimized antibiotic therapy of co-infections are of great importance and commend their antibiotic stewardship. Using a multiplex PCR method, authors report an incidence of 40.6% bacterial superinfections. This incidence is not reflected in our local population and recent literature and is therefore an interesting point of discussion.

During the period of March 12 to July 27, 2020, 83 consecutive patients were admitted to the intensive care unit (ICU) of our teaching hospital in Amsterdam, the Netherlands, of whom 18 were transferred to other hospitals. Of the 65 remaining patients, 51 were intubated for mechanical ventilation. Of these, 3 died within 48 h without collection of a tracheal aspirate, leaving 48 patients of whom a tracheal aspirate was obtained. A bacterial superinfection was cultured in 6 patients (12.5%), comprising Staphylococcus aureus (n = 5) and Pseudomonas aeruginosa (n = 1). All patients received selective decontamination of the digestive tract (SDD) after admission to the ICU to reduce colonization with antibiotic-resistant gram-negative bacteria. This consisted of enteral application of amphotericin B, tobramycin and colistin during the whole ICU admission, in combination with a short initial course of intravenous cefotaxime.

Our incidence of bacterial co-infection within 48 h of ICU admission is much lower than in the reported study. A recent meta-analysis described an incidence of bacterial co-infections of 14% in ICU COVID-19 patients [2]. Explanations for the differences in microbiological infection rate could be local epidemiology of pathogens and antibiotic usage [3]. The involvement of SDD is unlikely since this is commenced after culture collection. However, an alternative explanation could be that the PCR method of Verroken et al. detected healthy microbiome of the respiratory tract, as the lungs, previously considered sterile in health, are now known to harbour microbiota.

The most relevant difference with our findings is the method of detection. We agree that adjudication of a relevant bacterial co-infection is challenging during COVID-19 infection. However, the use of PCR could potentially yield false positive results. Thereby, it is of interest which proportion of patients also had positive culture results.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

ICU:

Intensive care unit

SDD:

Selective decontamination of the digestive tract

References

  1. 1.

    Verroken A, Scohy A, Gérard L, Wittebole X, Collienne C, Laterre P-F. Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis. Crit Care. 2020;24:410.

    Article  Google Scholar 

  2. 2.

    Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Inf Secur. 2020;81:266–75.

    CAS  Google Scholar 

  3. 3.

    Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med. 2009;30:127–35.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Robert J Bosman for the acquiring of patient data for this study.

Funding

Not applicable

Author information

Affiliations

Authors

Contributions

MN analysed and interpreted the patient data and wrote the manuscript. SB analysed and interpreted the patient data. NJ analysed and interpreted the patient data and revised the manuscript. All authors read and approved the final manuscript.

Authors’ information

Not applicable

Corresponding author

Correspondence to Marieke B. Nieuwenhuis.

Ethics declarations

Ethics approval and consent to participate

The institutional review board (IRB) of the Amsterdam University Medical Center considered the study as not requiring informed consent.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nieuwenhuis, M.B., Van Biesen, S. & Juffermans, N.P. Response to “Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis”. Crit Care 24, 591 (2020). https://doi.org/10.1186/s13054-020-03308-4

Download citation